Wuxi Biologics (Cayman) Inc.

11/20/2026 | Press release | Distributed by Public on 11/19/2026 19:49

WuXi Biologics Receives PSS Procurement Success Awards 2026

WuXi Biologics Receives PSS Procurement Success Awards 2026

SHANGHAI, China, November 20, 2026 - WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has received the Category Strategy Award at the Procurement Success Awards 2026, organized by Procurement Success Summit (PSS). The award recognizes WuXi Biologics' innovative approach to embedding procurement within its corporate digital transformation, building a more resilient and agile global supply chain that supports operational excellence and creates greater value for clients.

As a world leading digital-native CRDMO, WuXi Biologics is integrating commercial analytics, global procurement, supplier management and risk governance into a unified decision-making framework. This has resulted in a systematic category procurement strategy that drives efficiency, cost optimization, operational performance and ultimately delivers greater value to clients.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are honored to receive this industry recognition. Strong procurement and supply capabilities are essential to ensuring reliable operations and consistently delivering for clients worldwide. With rapid growth of our global business , we will deepen collaboration with our value chain partners and further strengthen an efficient, agile, and resilient global procurement and supply network. Through execution excellence and enhanced supply assurance, we remain committed to supporting our clients' success and creating long-term value for our clients."

WuXi Biologics is building a resilient, efficient, and agile global supply chain through multi-sourcing, demand-driven material planning, digital inventory management, global logistics and trade management. The company is also deepening strategic collaboration with suppliers worldwide, and has achieved ISO 20400 Sustainable Procurement certification and an ISO 22301 certification for Business Continuity Management System (BCMS). This integrated approach strengthens sustainable procurement, supply chain risk management, and business continuity, ensuring reliable global operations and supporting the consistent advancement of client projects.

About Procurement Success Summit (PSS)

Procurement Success Summit (PSS) is the most influential procurement gathering in Asia Pacific. Founded in 2014, it serves the world's leading procurement executives and innovation leaders, and is regarded as the bellwether of procurement in Asia. Recognized as the top-level procurement award in the industry, the Procurement Success Awards honor outstanding achievements that advance the profession across strategic impact, innovation, transformation, collaboration, capability building, and organizational influence.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics - from concept to commercialization - for the benefit of patients worldwide*.

With over 14,000 employees in China, the United States, Ireland, Germany, and Singapore, including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence, WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of June 30, 2026, WuXi Biologics is supporting 1,064 integrated client projects, including 78 in Phase III and 28 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)

*The winner of the "2026 Best Contract Development & Manufacturing Organization Award" (ABEA)

Contacts

Business

[email protected]

Media

[email protected]

Wuxi Biologics (Cayman) Inc. published this content on November 20, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 20, 2026 at 01:49 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]